Enterprise Value
485.6M
Cash
438.5M
Avg Qtr Burn
N/A
Short % of Float
0.50%
Insider Ownership
9.62%
Institutional Own.
66.99%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Obicetrapib Details Heterozygous familial hypercholesterolemia | Phase 3 Data readout | |
Obicetrapib + ezetimibe Details Dyslipidemia, Hypercholesterolemia | Phase 2 Update | |
Obicetrapib Details Heterozygous familial hypercholesterolemia | Phase 2a Data readout |